A Phase 2 interventional study of Zilucoplan (RA101495) in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Ra Pharmaceuticals. Completed at 12 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-27.
Sponsored by Ra Pharmaceuticals (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia — 2 open to participants now, 3 under way, none of them phase 3. Hemoglobinuria, Paroxysmal · Australia.
Among the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2017, is one of 2 in phase 2, and was the 8th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →2 of the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia are open now. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in Australia, United States, France and 4 more countries
Women only
ADARx Pharmaceuticals, Inc. · Sites in Australia, United Kingdom
Ages 18+ · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 7
First in 2004; this study’s year is marked. 3 started in 2017.
This study's enrollment of 26 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 80 across the 12 interventional studies, 75 across the 3 observational. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 7 most frequent:
This study is registered under Ra Pharmaceuticals, one of the names counted as UCB S.A.. Under that name alone:
Ra Pharmaceuticals is the lead sponsor of 4 studies on the registry; none are open to participants now.
UCB S.A. has 3 studies filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety and efficacy of zilucoplan (RA101495) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). There will be two groups of patients in the study: the first group will include patients who have never received eculizumab for treatment of PNH. The second group will include patients who have received treatment with eculizumab for at least 6 months prior to the study. Patients will be treated with RA101495 for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (treatment naïve)
Drug: Zilucoplan (RA101495)
0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (previously on eculizumab)
Drug: Zilucoplan (RA101495)
0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Level.
The primary efficacy endpoint is the change-from-baseline in serum LDH levels during this period, defined as the mean LDH values of Weeks 6, 8, 10, and 12 minus the baseline value of LDH.
Time frame: Through Week 12 of the study
Changes From Baseline in Bilirubin Values
Changes from baseline at each of the scheduled post-baseline time-points
Time frame: Through Week 12 of the study
Total Hemoglobin
Changes from baseline at each of the scheduled post-baseline time-points
Time frame: Through Week 12 of the Study
Changes From Baseline in Free Hemoglobin Values
Changes from baseline at each of the scheduled post-baseline time-points
Time frame: Through Week 12 of the study
Haptoglobin Values
Changes from baseline at each of the scheduled post-baseline time-points
Time frame: Through Week 12 of the Study
Reticulocyte Values
Changes from baseline at each of the scheduled post-baseline time-points
Time frame: Through Week 12 of the Study
Hemoglobinuria Values
Changes from baseline at each of the scheduled post-baseline time-points; Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10. Where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.
Time frame: Through Week 12 of the Study
| Milestone | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) |
|---|---|---|
| Started | 10 | 16 |
| Completed | 10 | 8 |
| Not completed | 0 | 8 |
| Withdrew: Adverse event | 0 | 8 |
The primary efficacy endpoint is the change-from-baseline in serum LDH levels during this period, defined as the mean LDH values of Weeks 6, 8, 10, and 12 minus the baseline value of LDH.
| U/L | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) |
|---|---|---|
| Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Level. | -695.2 ± 589.2 | 216.7 ± 209.2 |
Changes from baseline at each of the scheduled post-baseline time-points
| umol/L | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) |
|---|---|---|
| Week 1 | 1.3 ± 7.2 | 1.9 ± 4.5 |
| Week 2 | 3.1 ± 7.7 | 4.4 ± 6.5 |
| Week 3 | 4.4 ± 9.0 | 6.8 ± 7.5 |
| Week 4 | 4.0 ± 6.7 | 4.3 ± 6.5 |
| Week 6 | 4.1 ± 7.4 | 3.8 ± 7.8 |
| Week 8 | 4.0 ± 6.1 | 4.4 ± 9.9 |
| Week 10 | 5.7 ± 10.9 | 1.5 ± 6.1 |
| Week 12 | 4.6 ± 11.8 | 0.9 ± 4.5 |
Changes from baseline at each of the scheduled post-baseline time-points
| g/L | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) |
|---|---|---|
| Week 1 | -1.5 ± 10.4 | -0.7 ± 7.1 |
| Week 2 | 1.6 ± 7.4 | 0.9 ± 5.4 |
| Week 3 | 4.3 ± 9.5 | -1.1 ± 9.0 |
| Week 4 | 2.7 ± 10.5 | -0.9 ± 5.1 |
| Week 6 | 3.6 ± 9.8 | -1.4 ± 5.3 |
| Week 8 | 3.1 ± 9.6 | -1.0 ± 7.6 |
| Week 10 | 4.5 ± 8.8 | -1.3 ± 8.7 |
| Week 12 | 6.9 ± 10.6 | 0.5 ± 7.2 |
Changes from baseline at each of the scheduled post-baseline time-points
| mg/dL | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) |
|---|---|---|
| Week 1 | -7.84 ± 8.37 | 3.55 ± 18.51 |
| Week 2 | -8.31 ± 9.07 | -1.00 ± 11.66 |
| Week 3 | -5.65 ± 10.25 | -0.21 ± 3.87 |
| Week 4 | -7.57 ± 8.12 | 16.90 ± 50.64 |
| Week 6 | -8.24 ± 9.19 | -3.53 ± 10.66 |
| Week 8 | -7.62 ± 9.07 | -2.39 ± 9.25 |
| Week 10 | -7.60 ± 9.03 | -2.02 ± 10.06 |
| Week 12 | -7.39 ± 10.10 | -2.23 ± 11.32 |
Changes from baseline at each of the scheduled post-baseline time-points
| g/L | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) |
|---|---|---|
| Week 1 | 0.090 ± 0.285 | 0.010 ± 0.019 |
| Week 2 | 0.080 ± 0.253 | -0.003 ± 0.007 |
| Week 3 | 0.006 ± 0.019 | -0.003 ± 0.007 |
| Week 4 | 0.012 ± 0.038 | -0.064 ± 0.180 |
| Week 6 | 0.000 ± 0.000 | -0.064 ± 0.180 |
| Week 8 | 0.004 ± 0.013 | -0.064 ± 0.180 |
| Week 10 | 0.000 ± 0.000 | -0.064 ± 0.180 |
| Week 12 | 0.000 ± 0.000 | -0.064 ± 0.180 |
Changes from baseline at each of the scheduled post-baseline time-points
| 10^12 cells/L (SI Units) | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) |
|---|---|---|
| Week 1 | -0.0113 ± 0.0494 | -0.0147 ± 0.0326 |
| Week 2 | -0.0157 ± 0.0591 | 0.0022 ± 0.0279 |
| Week 3 | -0.0099 ± 0.0584 | 0.0063 ± 0.0197 |
| Week 4 | -0.0137 ± 0.0439 | 0.0004 ± 0.0289 |
| Week 6 | 0.0000 ± 0.0538 | 0.0170 ± 0.0259 |
| Week 8 | -0.0042 ± 0.0619 | 0.0050 ± 0.0346 |
| Week 10 | -0.0060 ± 0.0608 | 0.0085 ± 0.0304 |
| Week 12 | -0.0047 ± 0.0570 | 0.0061 ± 0.0166 |
Changes from baseline at each of the scheduled post-baseline time-points; Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10. Where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.
| score on a scale | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) |
|---|---|---|
| Week 1 | -0.2 ± 2.3 | 0.8 ± 1.8 |
| Week 2 | 0.4 ± 2.2 | 0.1 ± 1.3 |
| Week 3 | 0.3 ± 2.7 | 0.7 ± 1.8 |
| Week 4 | -0.2 ± 2.0 | 0.4 ± 1.6 |
| Week 6 | 0.3 ± 2.5 | 0.8 ± 2.3 |
| Week 8 | -0.2 ± 2.3 | 0.3 ± 1.6 |
| Week 10 | 0.3 ± 2.9 | 0.9 ± 1.6 |
| Week 12 | -0.2 ± 2.9 | 0.0 ± 2.2 |
Collected over Through Week 12 of the study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A (Treatment Naive) | 0/10 (0%) | 2/10 (20%) | 10/10 (100%) |
| Cohort B (Previously on Eculizumab) | 0/16 (0%) | 1/16 (6.3%) | 15/16 (93.8%) |
| Event | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) |
|---|---|---|
| PyrexiaGeneral disorders | 1/10 | — |
| Febrile nonhaemolytic transfusion reactionInjury, poisoning and procedural complications | 1/10 | — |
| Urinary tract InfectionInfections and infestations | — | 1/16 |
| Event | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) |
|---|---|---|
| HaemolysisBlood and lymphatic system disorders | 0/10 | 7/16 |
| HeadacheNervous system disorders | 1/10 | 7/16 |
| Injection site bruisingGeneral disorders | 3/10 | 1/16 |
| Upper respiratory tract infectionInfections and infestations | 3/10 | 1/16 |
| Abdominal PainGastrointestinal disorders | 2/10 | 1/16 |
| DizzinessNervous system disorders | 2/10 | 3/16 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/10 | 0/16 |
| Abdominal Pain UpperGastrointestinal disorders | 0/10 | 3/16 |
| FatigueGeneral disorders | 1/10 | 3/16 |
| Back painMusculoskeletal and connective tissue disorders | 1/10 | 3/16 |
| Age, Categorical(Participants) | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 11 | 18 |
| >=65 years | 3 | 5 | 8 |
| Age, Continuous(years) | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) | Total |
|---|---|---|---|
| Mean | 59.4 ± 14.5 | 49.6 ± 18.5 | 53.4 ± 17.4 |
| Sex: Female, Male(Participants) | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) | Total |
|---|---|---|---|
| Female | 6 | 7 | 13 |
| Male | 4 | 9 | 13 |
| Race (NIH/OMB)(Participants) | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 10 | 14 | 24 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) | Total |
|---|---|---|---|
| New Zealand | 4 | 0 | 4 |
| Canada | 1 | 0 | 1 |
| Hungary | 1 | 1 | 2 |
| Finland | 1 | 2 | 3 |
| Denmark | 0 | 1 | 1 |
| United Kingdom | 2 | 3 | 5 |
| Australia | 0 | 5 | 5 |
| Germany | 1 | 4 | 5 |
| Weight(kg) | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) | Total |
|---|---|---|---|
| Mean | 77.77 ± 20.64 | 79.16 ± 14.86 | 78.63 ± 16.92 |
| Height(cm) | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) | Total |
|---|---|---|---|
| Mean | 168.25 ± 11.08 | 171.10 ± 8.69 | 170.00 ± 9.56 |
| BMI(kg/m2) | Cohort A (Treatment Naive) | Cohort B (Previously on Eculizumab) | Total |
|---|---|---|---|
| Mean | 27.30 ± 6.15 | 26.95 ± 4.14 | 27.08 ± 4.89 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Mar 2018, 12 months.
Results were first posted in Mar 2020, 1 year 11 months after primary completion.
Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 12 months is below that.
Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zilucoplan